The overarching goal of our research is to devise novel antitumour immunotherapeutic modalities that can cure cancer. We have developed a series of human cell-based artificial antigen-presenting cells (APC) that can generate in vitro large numbers of HLA class I-restricted CD8 T cells, class II-restricted CD4 T cells, polyclonal CD3 T cells and CD1d-restricted iNKT cells. Using these artificial APC, we are conducting basic, translational, and clinical research in human T cell immunology. We are particularly interested in understanding how the interactions between T cells and APC affect priming, expansion, persistence and differentiation of T cells. We also seek to clarify how this leads to the subsequent generation and maintenance of T cell memory. Aspiring researchers and trainees who are eager to conquer cancer by harnessing the power of immunity are welcome to our laboratory.
Gene Modification and Immunological Analyses for the Development of Immunotherapy Utilizing T Cells Redirected with Antigen-Specific Receptors.
Methods Mol Biol. 2019;2048:27-39
Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials.
Front Oncol. 2019;9:415
Chaperones of the class I peptide-loading complex facilitate the constitutive presentation of endogenous antigens on HLA-DP84GGPM87.
J Autoimmun. 2019 Aug;102:114-125
Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
Cancer Immunol Immunother. 2019 May;68(5):773-785
In vitro-generated MART-1-specific CD8 T cells display a broader T cell receptor repertoire than naïve ex vivo and tumor infiltrating lymphocytes.
Immunol Cell Biol. 2019 Jan 11;:
Sci Immunol. 2018 Dec 14;3(30):
Blood Adv. 2018 Dec 11;2(23):3506-3514
Trends Immunol. 2018 Nov 08;:
J Autoimmun. 2018 Oct 11;:
Senior Scientist, Princess Margaret Cancer Centre
Associate Director for Research, Tumor Immunotherapy Program, Princess Margaret Cancer Centre
Professor, Department of Immunology, University of Toronto
Clinician Scientist, Ontario Institute for Cancer Research